Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is InSilico Medicine Cayman TopCo Current Ratio?
InSilico Medicine Cayman TopCoFRA:O15 +3.96%20 Current Ratio is 13.99 as of Dec. 2025, which is 5081% above its 10-year median of 0.27. GuruFocus rates FRA:O15 with a GF Score™ of 20/100. The stock has 3 warning signs investors should review. Among 2,876 Software companies, InSilico Medicine Cayman TopCo ranks better than 97.29% on this metric.
InSilico Medicine Cayman TopCo has a current ratio of 13.99. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for InSilico Medicine Cayman TopCo's Current Ratio or its related term are showing as below:
FRA:O15'
s Current Ratio Range Over the Past 10 Years
Min: 0.17 Med: 0.27 Max: 13.99
Current: 13.99
During the past 4 years, InSilico Medicine Cayman TopCo's highest Current Ratio was 13.99. The lowest was 0.17. And the median was 0.27.
FRA:O15's Current Ratio is ranked better than 97.29% of 2876
companies
in the Software industry
Industry Median: 1.78
vs FRA:O15: 13.99
InSilico Medicine Cayman TopCo (FRA:O15) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
InSilico Medicine Cayman TopCo Current Ratio Related Terms
InSilico Medicine Cayman TopCo Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InSilico Medicine Cayman TopCo Current Ratio Chart
FRA:O15 vs MSFT, ORCL, PLTR: Current Ratio Comparison
For the Software - Infrastructure subindustry, InSilico Medicine Cayman TopCo's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InSilico Medicine Cayman TopCo Current Ratio vs Software Industry
For the Software industry and Technology sector, InSilico Medicine Cayman TopCo's Current Ratio distribution charts can be found below:
* The bar in red indicates where InSilico Medicine Cayman TopCo's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InSilico Medicine Cayman TopCo (FRA:O15) has a Current Ratio of 13.99 as of Dec. 2025. This is 5081% above median its historical median of 0.27. Over the past decade, InSilico Medicine Cayman TopCo's Current Ratio has ranged from 0.17 to 13.99. According to the industry distribution chart, InSilico Medicine Cayman TopCo ranks #78 out of 2876 companies in the Software industry, placing it in the top 2.7%.
Is InSilico Medicine Cayman TopCo's Current Ratio too high?
InSilico Medicine Cayman TopCo's current Current Ratio of 13.99 is 5081% above median its 10-year median of 0.27. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 13.99. The Software industry median Current Ratio is 1.78. InSilico Medicine Cayman TopCo's value of 13.99 is 686% above this industry median. Based on the distribution chart, InSilico Medicine Cayman TopCo ranks #78 out of 2876 companies in the Software industry, which is in the top quartile — a strong position relative to peers. Overall, InSilico Medicine Cayman TopCo has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does InSilico Medicine Cayman TopCo's Current Ratio compare to MSFT and ORCL?
According to the Software industry distribution chart, InSilico Medicine Cayman TopCo ranks #78 out of 2876 companies for Current Ratio. This places InSilico Medicine Cayman TopCo in the top 3% of its industry — outperforming the majority of peers. The industry median Current Ratio is 1.78. InSilico Medicine Cayman TopCo's value of 13.99 is 686% above this benchmark. Historically, InSilico Medicine Cayman TopCo's own Current Ratio has ranged from 0.17 to 13.99 over the past decade. While the company's 10-year median is 0.27 vs. the industry median of 1.78, InSilico Medicine Cayman TopCo has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Software company?
The median Current Ratio among Software companies is 1.78, based on 2,876 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InSilico Medicine Cayman TopCo's current Current Ratio of 13.99 is 686% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Software industry, the median Current Ratio is 1.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InSilico Medicine Cayman TopCo's current Current Ratio is 13.99, which is 5081% above median its own 10-year median of 0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InSilico Medicine Cayman TopCo stock overvalued right now?
InSilico Medicine Cayman TopCo (FRA:O15) has a current Current Ratio of 13.99. The current Current Ratio is 13.99, which is 5081% above median its 10-year median of 0.27 and 686% above the Software industry median of 1.78. InSilico Medicine Cayman TopCo's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For InSilico Medicine Cayman TopCo (FRA:O15), the current Current Ratio is 13.99 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
20GF Score
Get the complete analysis for FRA:O15
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:O15 has been successfully added to your 
